Crestor is a powerful drug used to treat high cholesterol. However, it can have some unexpected side effects that patients may not be aware of.

The FDA is providing up-to-date information about the risk of serious muscle damage, called rhabdomyolysis, in patients taking Crestor as well as similar drugs, called statins. This is a well-known, rare side effect of all statins. Rhabdomyolysis is a condition in which muscle cells break down. This floods the blood with muscle proteins, sometimes leading to fatal kidney failure.

The FDA has issued a public health advisory to further explain the risks and benefits of the cholesterol-lowering drug Crestor. The drug will now carry a new label that includes new recommended doses for patients at a higher risk of muscle damage, including Asian patients.

"The FDA is committed to providing Americans with the latest and most comprehensive information on the medicines they use," says Steven Galson, MD, MPH, acting director of the Center for Drug Evaluation and Research (CDER). “An FDA advisory on Crestor is part of an ongoing effort to notify the public of potentially significant emerging safety data so that they can make more informed choices about their medical care."

In June 2004, the FDA advised doctors to be careful about how they prescribe Crestor. In January 2005, Crestor's manufacturer, AstraZeneca Pharmaceuticals, reported that a patient died while taking Crestor.

The FDA says extensive review of the large amount of available data indicates that patients taking recommended doses of Crestor have a similar risk of rhabdomyolysis as patients taking other statin drugs. Other available statins include Lipitor, Pravachol, and Zocor.

Crestor's manufacturer is also reminding doctors that they should consider using lower starting doses of Crestor in some individuals. However, this does not eliminate the risk for serious side effects.

If you feel that you or a loved one has experienced harmful side effects while taking Crestor, contact us today to find out if you may have a personal injury claim.

  • Testosterone is a male sex hormone that naturally decreases in the body as a man ages. This dip in testosterone levels can cause symptoms such as such as fatigue, depression, low libido, decreased muscle mass, and increased body fat.

    In recent years, millions of American men have been prescribed testosterone replacement drugs to combat these typical signs of aging. In fact, the companies that make these “Low-T” drugs use aggressive marketing to encourage patients and doctors to continue using these products that can sometimes have dangerous side effects.

  • Thousands of American women have undergone surgery for the insertion of products known as transvaginal mesh or surgical mesh implants. This surgical procedure is done, typically in older women, to correct for the effects of pelvic organ prolapse, when the internal body structure requires additional support to prevent the sagging of organs such as the urethra, cervix, and rectum. Transvaginal mesh is intended to repair this issue and ensure fewer health problems going forward.

  • Trasylol (aprotinin) is a drug that was widely used in surgery to help reduce bleeding. This drug was injected during complex surgery, such as heart and liver surgery, with the main effect of the slowing down of fibrinolysis, the process by which blood clots break down. The goal was to reduce the need for blood transfusions and organ damage due to hypotension.

  • Viagra and the related drug Revatio (sildenafil), both formulated and sold by the drug company Pfizer, are used to treat erectile dysfunction (ED) and pulmonary hypertension. Millions of men have utilized these medications to remedy these conditions and improve their day-to-day quality of life.

  • Vioxx (rofecoxib) is a nonsteroidal anti-inflammatory drug (NSAID) that was prescribed and marketed for osteoarthritis, acute pain, and dysmenorrhea. Throughout its time on the market, millions of people around the world were prescribed this medication.

  • Voltaren (diclofenac) is a nonsteroidal anti-inflammatory drug used for reducing inflammation and relieving pain. It is used to treat primarily acute pain, inflammatory disorders, and dysmenorrhea.

    Following the news that Vioxx carries a markedly high risk of cardiovascular incidents and heart disease, all other NSAIDs came under scrutiny as well. While Vioxx was pulled from the market, Voltaren and many other NSAIDs continue to be sold and prescribed. However, it may be that Volatern carries as high a risk of heart attack or stroke as Vioxx.

  • Xarelto is a blood-thinning drug which is used to reduce the risk of blood clots and stroke in patients with atrial fibrillation or “AFib” (irregular heartbeat) or patients who are recovering from certain surgical operations.

  • Zofran (ondansetron) and its dissolvable sister drug Zuplenz are drugs originally developed to treat nausea in cancer patients. GlaxoSmithKline, the drug company responsible for Zofran, in an effort to capitalize on another segment of the market, encouraged the prescription of this medication for nausea in pregnant women.

  • Zoloft (sertraline) is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely prescribed in the United States. As of 2013, over 40 million Americans were prescribed Zoloft. It is primarily prescribed for major depressive disorder but can also be used for treating obsessive-compulsive disorder (OCD), panic disorder, and social anxiety disorder, in both adults and children.

  • Zyprexa (olanzapine) is an atypical antipsychotic approved in the United States for the treatment of bipolar disorder and schizophrenia. It is also prescribed by some doctors for off-label uses, with no documented proof of effectiveness.

    Some patients claim that Eli Lilly, the manufacturer of Zyprexa, did not properly warn patients about the potential side effects that can occur while taking this medication. It has been alleged that Zyprexa can actually cause diabetes and other illnesses. At the very least it appears that the drug can lead to non-trivial hyperglycemia in patients that already have diabetes.